2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2015
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
Moura F, Figueiredo V, Teles B, Barbosa M, Pereira L, Costa A, Carvalho L, Cintra R, Almeida O, Quinaglia e Silva J, Nadruz W, Sposito A, Study B. Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 2015, 243: 124-130. PMID: 26385505, DOI: 10.1016/j.atherosclerosis.2015.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBrachial ArteryCoronary AngiographyC-Reactive ProteinDiabetes MellitusDietEndothelium, VascularFemaleFollow-Up StudiesGlycated HemoglobinHumansInflammationMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionNitric OxidePatient AdmissionPercutaneous Coronary InterventionProspective StudiesRisk FactorsROC CurveSensitivity and SpecificityTreatment OutcomeConceptsST-elevation myocardial infarctionFlow-mediated dilationNon-diabetic STEMI patientsC-reactive proteinSTEMI patientsEndothelial functionFollow-upInflammatory responseLong-term risk of MACEIncident diabetesLower HbA1cMedian follow-upClinical follow-upDecreased endothelial functionNon-diabetic patientsRisk of MACEAdverse cardiac eventsAdverse clinical outcomesIncreased inflammatory responseROC curve analysisSudden cardiac deathMeasured plasma glucoseNon-fatal MIPercutaneous coronary interventionLong-term risk
2013
Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp
Moura F, Carvalho L, Cintra R, Martins N, Figueiredo V, Quinaglia e Silva J, Almeida O, Coelho O, Sposito A. Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp. AJP Endocrinology And Metabolism 2013, 306: e399-e403. PMID: 24347056, DOI: 10.1152/ajpendo.00566.2013.Peer-Reviewed Original ResearchConceptsQuantitative insulin sensitivity check indexEuglycemic-hyperinsulinemic clampHomeostatic model assessmentHOMA-IRInsulin sensitivityMyocardial infarctionSurrogate indexHomeostatic model assessment of insulin resistanceModel assessment of insulin resistanceConsecutive nondiabetic patientsHomeostatic model assessment of insulin sensitivityAssessment of insulin resistanceST-segment elevation MISurrogate indexes of insulin sensitivityInsulin sensitivity check indexIndices of insulin sensitivityAcute phase of myocardial infarctionReceiver operating characteristic curveAcute MI patientsAssessment of insulin sensitivityPhase of myocardial infarctionGold standard reference methodBland-Altman plotsOperating characteristics curvePoor patient outcomes
2011
High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction
Carvalho L, Cintra R, Moura F, Martins N, Quinaglia e Silva J, Coelho O, Sposito A, Group O. High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis 2011, 220: 231-236. PMID: 22018645, DOI: 10.1016/j.atherosclerosis.2011.09.044.Peer-Reviewed Original ResearchConceptsHDL-C levelsHDL-C quartilePlasma HDL-C levelsHDL-CC-peptideMyocardial infarctionAcute phaseStress hyperglycemiaInsulin sensitivityAssociated with HDL-C levelsConsecutive non-diabetic patientsNon-diabetic patientsAcute phase of MILow plasma HDL-C levelsAcute phase of myocardial infarctionST-segment elevationPhase of myocardial infarctionBeta-cell functionAssess insulin sensitivityPhase of MIImproved insulin sensitivityBlood glucose changesPlasma glucoseQuartilePlasma insulin